Screener
Assembly Biosciences ASMB Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Assembly Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211987
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Other accrued expenses | 2,664 | 7,749 |
| Deferred revenue from a related party | 29,076 | 36,904 |
| Operating lease liabilities - short-term | 590 | 569 |
| Total current liabilities | 34,997 | 48,780 |
| Operating lease liabilities - long-term | 1,901 | 2,059 |
| Total liabilities | 36,898 | 50,839 |
| Commitments and contingencies | ||
| Stockholders' equity |
Item 1. Financial Statements
FAQ
- What is Assembly Biosciences's total current liabilities?
- Assembly Biosciences (ASMB) reported total current liabilities of $35M in Q1 2026.
- How has Assembly Biosciences's total current liabilities changed year-over-year?
- Assembly Biosciences's total current liabilities decreased by 24.9% year-over-year, from $46.63M to $35M.
- What is the long-term trend for Assembly Biosciences's total current liabilities?
- Over 5 years (2020 to 2025), Assembly Biosciences's total current liabilities has grown at a 14.8% compound annual growth rate (CAGR), from $24.43M to $48.78M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Assembly Biosciences's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude